We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-2.69%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$407M
Cap. Flow
+$930M
Cap. Flow %
30.11%
Top 10 Hldgs %
53.08%
Holding
79
New
16
Increased
25
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.7M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$86.1M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$83.8M
4
GERN icon
Geron
GERN
+$83.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$73.4M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$125M
2
HRMY icon
Harmony Biosciences
HRMY
+$49.9M
3
NMRA icon
Neumora Therapeutics
NMRA
+$42.4M
4
GH icon
Guardant Health
GH
+$42.1M
5
GMAB icon
Genmab
GMAB
+$41.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
1
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$264M 8.54%
2,000,000
– –
GH icon
2
Guardant Health
GH
$18.9B
$232M 7.51%
5,443,721
-975,845
-15% -$42.1M
DVAX
3
DELISTED
Dynavax Technologies
DVAX
$231M 7.47%
17,791,486
– –
IMVT icon
4
Immunovant
IMVT
$7.8B
$162M 5.26%
9,500,000
+3,500,000
+58% +$73.2M
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.62B
$145M 4.7%
3,000,000
+2,000,000
+200% +$83.8M
IONS icon
6
Ionis Pharmaceuticals
IONS
$9.04B
$138M 4.46%
4,564,207
+2,630,279
+136% +$86.1M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$130M 4.21%
3,210,270
+1,720,270
+115% +$72.9M
CYTK icon
8
Cytokinetics
CYTK
$10.7B
$124M 4%
3,073,853
+573,853
+23% +$26.4M
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$109M 3.54%
5,000,000
+725,079
+17% +$20M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.83B
$105M 3.39%
14,294,420
+1,458,138
+11% +$11.2M
BBIO icon
11
BridgeBio Pharma
BBIO
$16.5B
$96.8M 3.13%
2,800,000
+1,980,838
+242% +$66.8M
TARS icon
12
Tarsus Pharmaceuticals
TARS
$2.53B
$76.2M 2.47%
+1,484,266
New +$73.4M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.14B
$72.5M 2.35%
5,380,449
+857,708
+19% +$14.6M
GPCR icon
14
Structure Therapeutics
GPCR
$3.38B
$71M 2.3%
4,100,000
+1,300,000
+46% +$31.8M
ETNB
15
DELISTED
89bio
ETNB
$67.7M 2.19%
9,316,333
+2,838,084
+44% +$24.8M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.43B
$65.3M 2.12%
5,500,000
+2,500,000
+83% +$41.8M
GERN icon
17
Geron
GERN
$911M
$60.7M 1.97%
38,176,251
+34,164,964
+852% +$83.2M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.64B
$57.4M 1.86%
+899,731
New +$94.7M
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.48B
$48.9M 1.58%
1,350,000
+696,487
+107% +$29M
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.84B
$46.9M 1.52%
700,000
+50,958
+8% +$3.04M
DNTH icon
21
Dianthus Therapeutics
DNTH
$5.59B
$42.8M 1.38%
+2,357,702
New +$52M
IMCR icon
22
Immunocore
IMCR
$1.68B
$41.9M 1.36%
1,411,402
+892,026
+172% +$26.8M
CLDX icon
23
Celldex Therapeutics
CLDX
$2.84B
$36.3M 1.18%
2,000,000
+459,868
+30% +$10.3M
MAZE
24
Maze Therapeutics
MAZE
$1.51B
$36M 1.17%
+3,269,126
New +$39.4M
AMGN icon
25
Amgen
AMGN
$210B
$35.2M 1.14%
+113,035
New +$33.4M
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Deep Track Capital held 79 positions worth $3.09B, up 15% from $2.68B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital deployed $930M of net new capital in Q1 2025, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Sarepta Therapeutics: 899,731 shares worth $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Guardant Health, an estimated $42.1M trimmed.

  • Deep Track Capital's largest Q1 2025 buy was Sarepta Therapeutics: 899,731 shares worth $57.4M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2025, an estimated $86.1M increase.
  • Deep Track Capital's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $42.1M.
  • Deep Track Capital fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $125M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.09B portfolio in Q1 2025.
  • Deep Track Capital opened 16 new positions and closed 10 in Q1 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.09B.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.